Cargando…
A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451140/ https://www.ncbi.nlm.nih.gov/pubmed/35925787 http://dx.doi.org/10.1089/mab.2021.0068 |
_version_ | 1784784675403726848 |
---|---|
author | Bu, Melissa T. Yuan, Long Klee, Alyssa N. Freeman, Gordon J. |
author_facet | Bu, Melissa T. Yuan, Long Klee, Alyssa N. Freeman, Gordon J. |
author_sort | Bu, Melissa T. |
collection | PubMed |
description | Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents. |
format | Online Article Text |
id | pubmed-9451140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-94511402022-09-08 A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies Bu, Melissa T. Yuan, Long Klee, Alyssa N. Freeman, Gordon J. Monoclon Antib Immunodiagn Immunother Short Communications Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents. Mary Ann Liebert, Inc., publishers 2022-08-01 2022-08-25 /pmc/articles/PMC9451140/ /pubmed/35925787 http://dx.doi.org/10.1089/mab.2021.0068 Text en © Melissa T. Bu et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by-nc/4.0/This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License [CC-BY-NC] (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited. |
spellingShingle | Short Communications Bu, Melissa T. Yuan, Long Klee, Alyssa N. Freeman, Gordon J. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies |
title | A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies |
title_full | A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies |
title_fullStr | A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies |
title_full_unstemmed | A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies |
title_short | A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies |
title_sort | comparison of murine pd-1 and pd-l1 monoclonal antibodies |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451140/ https://www.ncbi.nlm.nih.gov/pubmed/35925787 http://dx.doi.org/10.1089/mab.2021.0068 |
work_keys_str_mv | AT bumelissat acomparisonofmurinepd1andpdl1monoclonalantibodies AT yuanlong acomparisonofmurinepd1andpdl1monoclonalantibodies AT kleealyssan acomparisonofmurinepd1andpdl1monoclonalantibodies AT freemangordonj acomparisonofmurinepd1andpdl1monoclonalantibodies AT bumelissat comparisonofmurinepd1andpdl1monoclonalantibodies AT yuanlong comparisonofmurinepd1andpdl1monoclonalantibodies AT kleealyssan comparisonofmurinepd1andpdl1monoclonalantibodies AT freemangordonj comparisonofmurinepd1andpdl1monoclonalantibodies |